These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 28365538)
1. Co-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis C. Fialho R; Pereira M; Harrison N; Rusted J; Whale R Psychiatry Res; 2017 Jul; 253():150-157. PubMed ID: 28365538 [TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125 [TBL] [Abstract][Full Text] [Related]
3. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. Yaya I; Roux P; Marcellin F; Wittkop L; Esterle L; Spire B; Dominguez S; Elegbe BA; Piroth L; Sogni P; Salmon-Ceron D; Carrieri MP; PLoS One; 2018; 13(7):e0199874. PubMed ID: 29975764 [TBL] [Abstract][Full Text] [Related]
4. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225 [TBL] [Abstract][Full Text] [Related]
5. INCIDENCE OF TUBERCULOSIS AMONG HIV/HCV CO-INFECTED PATIENTS RECEIVING HEPATITIS C TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN GEORGIA. Abutidze A; Bolokadze N; Chkhartishvili N; Sharvadze L; Tsertsvadze T Georgian Med News; 2016 Mar; (252):10-5. PubMed ID: 27119828 [TBL] [Abstract][Full Text] [Related]
6. Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. Gonvers JJ; Heim MH; Cavassini M; Müllhaupt B; Genné D; Bernasconi E; Borovicka J; Cerny A; Chave JP; Chuard C; Dufour F; Dutoit V; Malinverni R; Monnat M; Negro F; Troilliet N; Oneta C Swiss Med Wkly; 2010; 140():w13055. PubMed ID: 20648398 [TBL] [Abstract][Full Text] [Related]
7. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study. Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B; Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715 [TBL] [Abstract][Full Text] [Related]
8. High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic. Kieran J; Dillon A; Farrell G; Jackson A; Norris S; Mulcahy F; Bergin C Int J STD AIDS; 2011 Oct; 22(10):571-6. PubMed ID: 21998177 [TBL] [Abstract][Full Text] [Related]
9. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Klein MB; Cooper C; Brouillette MJ; Sheehan NL; Benkelfat C; Annable L; Weston F; Kraus D; Singer J; Contemp Clin Trials; 2008 Jul; 29(4):617-30. PubMed ID: 18262853 [TBL] [Abstract][Full Text] [Related]
10. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; Martínez-Marcos F; Ortega-González E; Real LM; Pernas B; Merchante N; Cid P; Macías J; Merino MD; Rivero A; Mena A; Neukam K; Pineda JA; Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):1929-36. PubMed ID: 26155784 [TBL] [Abstract][Full Text] [Related]
11. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093 [TBL] [Abstract][Full Text] [Related]
12. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy. Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330 [TBL] [Abstract][Full Text] [Related]
13. A longitudinal study assessing depression in hepatitis C: Does gender play a role in the new-onset depression during interferon-alpha treatment? Fialho R; Pereira M; Gilleece Y; Rusted J; Whale R Women Health; 2019 Feb; 59(2):181-195. PubMed ID: 29630491 [TBL] [Abstract][Full Text] [Related]
14. [Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy]. Ke YC; Li LH; Hu FY; He Y; Lan Y; Chen XJ; Tang XP; Cai WP Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):181-5. PubMed ID: 27095760 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067 [TBL] [Abstract][Full Text] [Related]
16. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users. Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP; Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472 [TBL] [Abstract][Full Text] [Related]
17. Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients. Ioannou GN; Scott JD; Yang Y; Green PK; Beste LA Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1373-84. PubMed ID: 24127691 [TBL] [Abstract][Full Text] [Related]
18. Psychomotor retardation and vulnerability to interferon alpha induced major depressive disorder: Prospective study of a chronic hepatitis C cohort. Whale R; Fialho R; Rolt M; Eccles J; Pereira M; Keller M; File A; Haq I; Tibble J J Psychosom Res; 2015 Dec; 79(6):640-5. PubMed ID: 26117091 [TBL] [Abstract][Full Text] [Related]
19. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J; PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696 [TBL] [Abstract][Full Text] [Related]
20. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]